Pharmaceuticals & Therapeutics

Activist investor Altai Capital launches a proxy fight at OraSure, alleging chronic underperformance and demanding board seats to force a strategic review.

The Devil is in the details. A new partnership between Grey Goose and "The Devil Wears Prada 2" redefines brand engagement through film, fashion, and cocktails.

Aldeyra Therapeutics' dry eye drug, reproxalap, was rejected by the FDA for a third time, citing inconsistent data and wiping out millions in value.

A new injectable dye entering Phase 3 trials promises to make lung cancer cells glow, helping surgeons remove tumors more completely and prevent recurrence.

Consumers overcharged for generic drugs may get cash from a new $17.8M settlement. Find out if you're eligible and how this fits into a larger legal war.

A new collaboration will use Voro's 'masking' technology to create tumor-activated ADCs, aiming to make powerful cancer therapies safer and more effective.

Backed by dialysis giants DaVita and U.S. Renal Care, a new startup licenses a first-in-class therapy to transform treatment for kidney patients.

A new biotech firm unveils a first-in-class cancer drug targeting E6AP, aiming to restore the body's natural defenses against HPV-positive head and neck cancer.

Facing a challenging EV market, Aspen Aerogels looks to the Roth Conference to showcase its long-term growth strategy and advanced aerogel technology.

With promising clinical data for its lead drug silevertinib and a strong new financial position, Black Diamond Therapeutics charts a dual course for two deadly cancers.

JAMP Pharma Group introduces a generic version of a key prostate cancer drug, aiming to reduce healthcare costs and enhance patient support in Canada.

A new alliance aims to overhaul Alzheimer's research, demanding a precision approach for the 65% of patients carrying the high-risk APOE4 gene.

With over half of pets overweight, a renewed partnership is fighting the silent epidemic through science, nutrition, and accessible veterinary care.

San Diego biotech elevates key execs as it advances its inflammation pipeline, backed by Sanofi and Lilly, into a competitive and high-stakes market.

With its lead autoimmune drug nearing FDA review and a new $250M in funding, Zenas BioPharma prepares for a major leap from R&D to market.

The body contouring firm faces investor unease over a delayed annual report, even as it points to a sales rebound from a new marketing push.

The firm continues its monthly dividend while positioning its funds to capitalize on global instability, doubling down on defense, gold, and energy sectors.

Groundbreaking Hong Kong research uncovers why the common ‘Asian Flush’ gene dramatically worsens heart attack outcomes, paving the way for new treatments.

As employers grapple with soaring obesity drug costs, a new partnership aims to offer predictable pricing and comprehensive care. Here's how it works.

Aditxt's $36M acquisition of Ignite Proteomics aims to upend cancer therapy by analyzing protein activity, a high-stakes bet for the struggling innovator.